Craig Balog
Overview
Explore the profile of Craig Balog including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
183
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nissen S, Wolski K, Balog C, Swerdlow D, Scrimgeour A, Rambaran C, et al.
JAMA
. 2022 Apr;
327(17):1679-1687.
PMID: 35368052
Importance: Lipoprotein(a) (Lp[a]) is an important risk factor for atherothrombotic cardiovascular disease and aortic stenosis, for which there are no treatments approved by regulatory authorities. Objectives: To assess adverse events...
2.
Kataoka Y, Wolski K, Balog C, Uno K, Puri R, Tuzcu E, et al.
Eur Heart J Cardiovasc Imaging
. 2014 May;
15(9):1035-41.
PMID: 24780871
Aim: Large plaque burden, expansive vascular remodelling, and spotty calcification have been considered as important morphologies of high-risk plaques causing acute coronary events. Although non-occlusive rupture of high-risk plaques has...
3.
Bayturan O, Tuzcu E, Nicholls S, Balog C, Lavoie A, Uno K, et al.
JACC Cardiovasc Interv
. 2009 Jul;
2(7):672-8.
PMID: 19628192
Objectives: We investigated attenuated plaque (hypoechoic plaque with deep ultrasonic attenuation despite absence of bright calcium) in nonculprit lesions. Background: Recent intravascular ultrasound (IVUS) studies describe acoustic shadowing behind large,...
4.
Sipahi I, Tuzcu E, Wolski K, Nicholls S, Schoenhagen P, Hu B, et al.
Ann Intern Med
. 2007 Jul;
147(1):10-8.
PMID: 17606956
Background: In patients with myocardial infarction, beta-adrenergic blockers reduce recurrent myocardial infarction and total mortality rates. However, whether a direct influence of beta-blockers on coronary atherosclerosis contributes to reduced recurrent...
5.
Sipahi I, Tuzcu E, Schoenhagen P, Wolski K, Nicholls S, Balog C, et al.
J Am Coll Cardiol
. 2006 Aug;
48(4):833-8.
PMID: 16904557
Objectives: The purpose of this study was to evaluate the effects of normal blood pressure (BP), pre-hypertension, and hypertension on progression of coronary atherosclerosis. Background: The Seventh Report of the...
6.
Blankenship J, Balog C, Sapp S, Califf R, Lincoff A, Tcheng J, et al.
Catheter Cardiovasc Interv
. 2002 Nov;
57(4):476-83.
PMID: 12455081
We analyzed vascular access site bleeding from the EPIC, EPILOG, and EPISTENT trials to quantify the decrease in vascular bleeding complications in these three trials, especially those attributable to abciximab....
7.
Islam M, Blankenship J, Balog C, Iliadis E, Lincoff A, Tcheng J, et al.
Am J Cardiol
. 2002 Oct;
90(9):916-21.
PMID: 12398954
In the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT), abciximab reduced ischemic complications of stent implantation at 30 days and 6 months. The responsible mechanisms remain unclear. We...
8.
Mazur W, Kaluza G, Sapp S, Balog C, Topol E, Mark D, et al.
Am Heart J
. 2002 Mar;
143(4):594-601.
PMID: 11923795
Background: Angiographic features of vessels in which stents have been deployed can be used to predict the risk of postprocedural ischemic events. The purpose of this study was to compare...